The concept of controlling chronic obstructive pulmonary disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Given the significant heterogeneity of the disease, the treatment of chronic obstructive pulmonary disease (COPD) should be individualized, taking into account the different clinical characteristics and severity of the condition of each patient. That is why experts proposed a new concept for controlling COPD. Clinical COPD control may be a new step in determining the status of a patient after assessing the phenotype, severity of the disease, severity of symptoms, taking into account the degree of impaired respiratory function, associated diseases, prognostic parameters. The concept of COPD control is interpreted as maintaining the situation with the minimal clinical impact of disease symptoms in combination with a stable course characterized by a low risk of exacerbations over a long period of time adapted to the severity of the disease. Different clinical criteria for controlling require further research to confirm a high level of correlation with different clinical outcomes in a controlled or uncontrolled course of COPD. The authors of the concept suggest using the possibilities of drug therapy to correct the level of control. Modifying the amount of therapy based on the level of control implies periods of increasing the volume of therapy due to the addition of drugs of another class with insufficient control and periods of ongoing therapy with a good level of control. It is also possible to reduce the amout of therapy by canceling inhaled glucocorticosteroids in patients whose disease remains controlled for a certain period of time. The amount of bronchodilation therapy in COPD is not recommended to be reduced, since this is progressive disease and full normalization of the functional respiratory parameters is impossible. Such an approach would help to correct the treatment of each patient, avoiding both insufficient and excessive medication effects, and achieve the best possible course of the disease with a minimum amount of therapy.

Full Text

Restricted Access

About the authors

Yuliya G. Belotserkovskaya

Russian Medical Academy of Continuous Professional Education

Email: belo-yuliya@yandex.ru
PhD, Associate Professor at the Department of Pulmonology

A. I Sinopalnikov

Russian Medical Academy of Continuous Professional Education

A. G Romanovskikh

Russian Medical Academy of Continuous Professional Education

I. P Smirnov

Russian Medical Academy of Continuous Professional Education

References

  1. The Global Strategy for Diagnosis, Management and Prevention of COPD (updated 2019) is available on the GOLD website: https://goldcopd. org/wp-con ten t/uploads/2018/11/G0LD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.
  2. Adeloye D., Chua S., Lee C., et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Global Health. 2015;5(2):020415. Doi: 10.7189/ jogh.05-020415.
  3. Global Burden of Disease Study Collaborators. Global, regional, and national age-sex specific allcause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. Doi: https://doi. org/10.1016/S0140-6736(14)61682-2.
  4. Lopez A.D., Shibuya K., Rao C., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397 412. doi: 10.1183/09031936.06.00025805
  5. World Health Organization. Projections of mortality and causes of death, 2015 and 2030.
  6. Agusti A., MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68:687-90.
  7. Miravitlles M., Soler-Cataluna J.J., Calle M., et al. Treatment of COPD by clinical phenotypes: putting old evidenceinto clinical practice. Eur Respir J. 2013;41:1252-56. doi: 10.1183/09031936.00118912.
  8. McDonald V., Higgins I., Wood L.G., et al. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68:691-94. doi: 10.1186/1465-9921-14-24.
  9. Han M.K., Agusti A., Calverley PM., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598-604.
  10. Soler-Cataluna J.J., Alcazar-Navarrete B., Mira-vitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397-405.
  11. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005-12. doi: 10.1056/NEJMoa021322.
  12. Soler-Cataluna J.J., Martinez-Garcia M.A., Sanchez L., et al. Severe exacerbations and BODE index: two independentrisk factors for death in male COPD patients. Respir Med. 2009;103:692 99. doi: 10.1016/j.rmed.2008.12.005
  13. Agusti' A., Calverley PM.A., Celli B., et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122. doi: 10.1186/1465-9921-11-122.
  14. Agusti A., Soler J.J., Molina J., et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD. 2012;9(5):492-98. doi: 10.3109/15412555.2012.692409.
  15. Miravitlles M., Garda-Sidro P, Fernandez-Nistal A., et al. Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease. Health Qual. Life Outcomes. 2013;11:147.
  16. DuarteAraOjo A., Hespanhol V, Correia-de-Sousa J. Is COPD control a useful concept? Assessing treatment success by evaluating COPD-related health status. Arch Bronconeumol. 2017;53(9):530-31.
  17. Langer D, Demeyer H., Troosters T., Gosselink R. The importance of physical activity. Eur Respir Monogr. 2015;69:224-39.
  18. Waschki B., Kirstem A., Holz O., et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331-42.
  19. Nibber A, Chisholm A., Soler-Cataluna J.J., et al. Validating the concept of COPD control: a real-world cohort study from the United Kingdom. COPD. 2017;14(5):504-12. doi: 10.1080/15412555.2017.1350154.
  20. Miravitlles M., Sliwinski P, Rhee C.K., et al. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respir Med. 2018;136:8-14.
  21. Soler-Cataluna J., Marzo M., Catalon P, et al. Validation of clinical control in COPD as a new tool for optimizing treatment. Intern J. COPD. 2018:13.
  22. Miravitlles M., Sicras A., Crespo C., et al. Costs of COPD in relation to compliance with guidelines. A study in the Primary Care setting. Ther Adv Respir Dis. 2013;7(3):139-50. doi: 10.1177/1753465813484080.
  23. Ghattas C., Dai A., Gemmel D.J., Award M.H. Over diagnosis of chronic obstructive pulmonary disease in an underserved patient population. Int J Chron Obst Pulm Dis. 2013;8:545-49. Doi: 10.2147/ COPD.S4569.
  24. Al-Kassimi F.A., Alhamad E.H., Al-Hajjaj M.S., et al. Abrupt withdrawal of inhaled corticosteroids does not result in spirometric deterioration in chronic obstructive pulmonary disease: effect of phenotyping? Ann Thorac Med. 2012; 7(4):240-42.
  25. Nadeem N.J., Taylor S.J., Eldridge S.M. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment of trial methodology. Respir Res. 2011;12:107. doi: 10.1186/1465-9921-12-107.
  26. Siddiqui S.H., Guasconi A., Vestbo J., et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192(4):523-25. Doi: 10.1164/ rccm.201502-0235LE.
  27. Papi A., Vestbo J., Fabbri L., et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125): 1076-84. doi: 10.1016/S0140-6736(18) 30206-X.
  28. Pascoe S., Locantore N., Dransfield M.T., et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet. Respir Med. 2015;3(6):435-42.
  29. Vestbo J., Papi A., Corradi M., et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919 29. doi: 10.1016/S0140-6736(17)30188-5
  30. Roche N., Chapman K.R., Vogelmeier C.F, et al. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. Am J Respir Crit Care Med. 2017;195(9):1189-97. Doi: 10.1164/ rccm.201701-0193OC.
  31. Watz H., Tetzlaff K., Wouters E.F, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet. Respir Med. 2016;4(5):390-98. doi: 10.1016/S2213-2600(16)00100-4.
  32. Calverley PM.A., Tetzlaff K., Vogelmeier C., et al. Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(9):1219 21. doi: 10.1164/rccm.201612-2525LE
  33. Crim C., Dransfield M.T., Bourbeau J., et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thor Soc. 2015;12(1):27-34.
  34. Crim C., Calverley PM.A., Anderson J.A., et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respir Med. 2017;131:27-34.
  35. Pavord I.D., Lettis S., Anzueto A., Barnes N. Bloode osinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: apatient-levelmeta-analysis. Lancet. Respir Med. 2016;4(9):731-41. Doi: http://dx.doi. org/10.1016/S2213-2600(16)30148-5.
  36. Johnell O., Pauwels R., Lofdahl C.G., et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J. 2002;19(6):1058-63.
  37. Ferguson G.T., Calverley PM., Anderson J.A., et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009;136(6):1456-65. doi: 10.1378/chest.08-3016.
  38. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699-708.
  39. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-6.
  40. Wang J.J., Rochtchina E., Tan A.G., et al. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmol. 2009;116(4):652 57. doi: 10.1016/j.ophtha.2008.12.001
  41. Andrejak C., Nielsen R., Thomsen V.O., et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256-62.
  42. Dong Y.H., Chang C.H., Lin Wu F.L., et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(6):1286-97. Doi: http:// dx.doi.org/10.1378/chest.13-2137.
  43. Lee C.H., Kim K., Hyun M.K., et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68(12):1105-13.
  44. Price D, Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92 100. doi: 10.4104/pcrj.2012.00092
  45. Vestbo J., Vogelmeier C., Small M., Higgins V Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Respir Med. 2014;108(5):729-36
  46. Safka K.A., Wald J., Wang H., et al. GOLD stage and treatment in COPD: a 500 patient point prevalence study. Chronic Obstr Pulm Dis. 2017;4(1):45 55. Doi: http://doi.org/10.15326/jcopdf.4.1. 2016.0126
  47. Brusselle G., Price D., Gruffydd-Jones K., et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK Int J Chronic Obstr Pulm Dis. 2015;10:2207-17. doi: 10.2147/COPD.S91694.
  48. Chapman K.R., Hurst J.R., Frent S.M., et al. Longterm Triple Therapy De-escalation to Indacaterol/ Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med. 2018.
  49. Wedzicha J.A., Banerji D., Chapman K.R., et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222-34. Doi: 10.1056/ NEJMoa1516385.
  50. Vogelmeier C., Chapman K.R., Miravitlles M., et al. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. Int J COPD. 2018;13:1125-34.
  51. Singh D., Worsley S., Zhu C., et al. Umeclidinium/ vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC. Pulm Med. 2015;15:91. doi: 10.1186/s12890-015-0092-1.
  52. Vogelmeier C., Paggiaro P., Dorca J., et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48:1030-39.
  53. Kessler R., Stahl E., Vogelmeier C., et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006;130:133e42. Doi: 10.1378/ chest.130.1.133.
  54. Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847e52.
  55. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. Updated 2011. Available at: http://www.goldcopd.org/ uploads/users/files/GOLD_Report_2011 _ Feb21.pdf.
  56. Wilkinson T.M., Donaldson G.C., Hurst J.R., et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298e303.
  57. Sullivan S.D., Ramsey S.D., Lee T.A. TheeconomicburdenofCOPD. Chest. 2000; 117(Suppl. 2):5Se9S.
  58. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(Suppl. 41):46se53s.
  59. Sharafkhaneh А., Altan A.E., Colice G.L., et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014;108:1310-20.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies